It’s only fair to share… Palacaparib CAS 2756333-39-6 MFC21H22F2N6O2 MW428.4 g/mol 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl- 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, AZD 9574, 9UG32UQW48 Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.[1] It is a selective PARP1 inhibitor.[2][3] Palacaparib (also known as AZD9574) is an investigational, orally bioavailable cancer drug developed by AstraZeneca. It belongs to …
Tag «poly (ADP-ribose) polymerase (PARP) inhibitor»
Itareparib
It’s only fair to share… Itareparib CAS 1606995-47-4 MF C20H26FN3O2 MW359.4 g/mol 2-(1-Cyclohexyl-4-piperidinyl)-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide 1H-ISOINDOLE-4-CARBOXAMIDE, 2-(1-CYCLOHEXYL-4-PIPERIDINYL)-6-FLUORO-2,3-DIHYDRO-3-OXO- 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole4-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, NMS-03305293, NMS-293, NMS 03305293, NMS 293, KFI1190L8L, NV 578, Itareparib is the inhibitor for PARP and exhibits antineoplastic activity. Itareparib (development code NMS-03305293 or NMS-293) is an experimental, next-generation PARP1-selective oral inhibitor being developed by the biopharmaceutical …